Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis

esRAGE serum levels are modulated by DMDs. The serum levels may be a useful biomarker of MS clinical relapse.